Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review

Chest

Volumn 151, Issue 1, 2017, Pages 127-138

  Samuelson, Bethany T ^a   Cuker, Adam ^b   Siegal, Deborah M ^c   Crowther, Mark ^c   Garcia, David A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

antithrombotic therapy; deep venous thrombosis; direct oral anticoagulants; laboratory; pulmonary embolism

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; EDOXABAN; RIVAROXABAN; ANTITHROMBIN;

ANTICOAGULATION; ARTICLE; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; EVIDENCE BASED MEDICINE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; MEASUREMENT ACCURACY; PARTIAL THROMBOPLASTIN TIME; PERFORMANCE; RELIABILITY; STANDARD; SYSTEMATIC REVIEW; THROMBIN TIME; VENOUS THROMBOEMBOLISM; ATRIAL FIBRILLATION; BLOOD; BLOOD CLOTTING; COMPLICATION; DRUG EFFECTS; DRUG MONITORING; PROCEDURES;

ANTITHROMBINS; ATRIAL FIBRILLATION; BLOOD COAGULATION; DRUG MONITORING; HUMANS; VENOUS THROMBOEMBOLISM;

EID: 85009758558     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.08.1462     Document Type: Article

References (121)

1. 1 Kearon, C., Akl, E.A., Comerota, A.J., et al., and the American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed—American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:2 suppl (2012), e419S–e494S.
2. 2 Ansell, J.E., Management of venous thromboembolism: clinical guidance from the Anticoagulation Forum. J Thromb Thrombolysis 41:1 (2016), 1–2.
3. 3 January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130:23 (2014), e199–e267.
4. 4 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:12 (2009), 1139–1151.
5. 5 Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:11 (2011), 981–992.
6. 6 Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:10 (2011), 883–891.
7. 7 Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:22 (2013), 2093–2104.
8. 8 Martin, K., Moll, S., Direct oral anticoagulant drug level testing in clinical practice: a single institution experience. Thromb Res 143 (2016), 40–44.
9. 9 Cuker, A., Siegal, D.M., Crowther, M.A., et al. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64:11 (2014), 1128–1139.
10. 10 Ageno, W., Gallus, A.S., Wittkowsky, A., Crowther, M., Hylek, E.M., Palareti, G., and the American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:2 suppl (2012), e44S–e88S.
11. 11 Baglin T, Hillarp A, Tripodi A, et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis [published online ahead of print January 24, 2013]. J Thromb Haemost. http://dx.doi.org/10.1111/jth.12149.
12. 12 Cuker, A., Husseinzadeh, H., Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis 39:3 (2015), 288–294.
13. 13 Stangier, J., Clemens, A., Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 15:suppl 1 (2009), 9S–16S.
14. 14 Antovic, J.P., Skeppholm, M., Eintrei, J., et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 69:11 (2013), 1875–1881.
15. 15 Avecilla, S.T., Ferrell, C., Chandler, W.L., et al. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol 137:4 (2012), 572–574.
16. 16 Bonar, R., Favaloro, E.J., Mohammed, S., et al. The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 47:4 (2015), 355–364.
17. 17 Chin, P.K., Patterson, D.M., Zhang, M., et al. Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. Br J Clin Pharmacol 78:3 (2014), 630–638.
18. 18 Dager, W.E., Gosselin, R.C., Kitchen, S., et al. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother 46:12 (2012), 1627–1636.
19. 19 Delavenne, X., Moracchini, J., Laporte, S., et al. UPLC MS/MS assay for routine quantification of dabigatran—a direct thrombin inhibitor—in human plasma. J Pharm Biomed Anal 58 (2012), 152–156.
20. 20 Dias, J.D., Norem, K., Doorneweerd, D.D., et al. Use of thromboelastography (TEG) for detection of new oral anticoagulants. Arch Pathol Lab Med 139:5 (2015), 665–673.
21. 21 Dietrich, K., Stang, L., van Ryn, J., et al. Assessing the anticoagulant effect of dabigatran in children: an in vitro study. Thromb Res 135:4 (2015), 630–635.
22. 22 Douxfils, J., Dogne, J.M., Mullier, F., et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 110:3 (2013), 543–549.
23. 23 Douxfils, J., Mullier, F., Robert, S., et al. Impact of dabigatran on a large panel of routine or specific coagulation assays: laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 107:5 (2012), 985–997.
24. 24 Gosselin, R.C., Adcock, D., Hawes, E.M., et al. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban. Thromb Haemost 113:1 (2015), 77–84.
25. 25 Gosselin, R.C., Dwyre, D.M., Dager, W.E., Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother 47:12 (2013), 1635–1640.
26. 26 Halbmayer, W.M., Weigel, G., Quehenberger, P., et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med 50:9 (2012), 1601–1605.
27. 27 Harenberg, J., Giese, C., Marx, S., et al. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 38:1 (2012), 16–22.
28. 28 Hartter, S., Yamamura, N., Stangier, J., et al. Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. Thromb Haemost 107:2 (2012), 260–269.
29. 29 Hawes, E.M., Deal, A.M., Funk-Adcock, D., et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 11:8 (2013), 1493–1502.
30. 30 He, S., Wallen, H., Bark, N., et al. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban. J Thromb Thrombolysis 35:2 (2013), 131–139.
31. 31 Jones, S.D., Eaddy, N.S., Chan, G.T., Dabigatran: laboratory monitoring. Pathology 44:6 (2012), 578–580.
32. 32 Liesenfeld, K.H., Schaefer, H.G., Troconiz, I.F., et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 62:5 (2006), 527–537.
33. 33 Lindahl, T.L., Baghaei, F., Blixter, I.F., et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 105:2 (2011), 371–378.
34. 34 Schmohl, M., Gansser, D., Moschetti, V., et al. Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis. Thromb Res 135:3 (2015), 532–536.
35. 35 Sinigoj, P., Malmstrom, R.E., Vene, N., et al. Dabigatran concentration: variability and potential bleeding prediction in “real-life” patients with atrial fibrillation. Basic Clin Pharmacol Toxicol 117:5 (2015), 323–329.
36. 36 Skeppholm, M., Hjemdahl, P., Antovic, J.P., et al. On the monitoring of dabigatran treatment in “real life” patients with atrial fibrillation. Thromb Res 134:4 (2014), 783–789.
37. 37 Stangier, J., Feuring, M., Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 23:2 (2012), 138–143.
38. 38 Stangier, J., Rathgen, K., Stahle, H., et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:3 (2007), 292–303.
39. 39 Stangier, J., Stahle, H., Rathgen, K., et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47:1 (2008), 47–59.
40. 40 Van Blerk, M., Bailleul, E., Chatelain, B., et al. Influence of dabigatran and rivaroxaban on routine coagulation assays: a nationwide Belgian survey. Thromb Haemost 113:1 (2015), 154–164.
41. 41 van Ryn, J., Baruch, L., Clemens, A., Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 125:4 (2012), 417–420.
42. 42 Douxfils, J., Lessire, S., Dincq, A.S., et al. Estimation of dabigatran plasma concentrations in the perioperative setting: an ex vivo study using dedicated coagulation assays. Thromb Haemost 113:4 (2015), 862–869.
43. 43 Eller, T., Busse, J., Dittrich, M., et al. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clin Chem Lab Med 52:6 (2014), 835–844.
44. 44 Wilson, J.A., Goralski, K.B., Soroka, S.D., et al. An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. J Clin Pharmacol 54:8 (2014), 901–909.
45. 45 Douxfils, J., Chatelain, B., Hjemdahl, P., et al. Does the Russell viper venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thromb Res 135:5 (2015), 852–860.
46. 46 Dinkelaar, J., Molenaar, P.J., Ninivaggi, M., et al. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban. J Thromb Haemost 11:6 (2013), 1111–1118.
47. 47 Meyer Dos Santos, S., Zorn, A., Guttenberg, Z., et al. A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants. Biomicrofluidics, 7(5), 2013, 56502.
48. 48 Helin, T.A., Pakkanen, A., Lassila, R., et al. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem 59:5 (2013), 807–814.
49. 49 Perzborn, E., Strassburger, J., Wilmen, A., et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct factor Xa inhibitor. J Thromb Haemost 3:3 (2005), 514–521.
50. PrXarelto. http://omr.bayer.ca/omr/online/xarelto-pm-en.pdf. Accessed October 12, 2015.
51. 51 Kubitza, D., Becka, M., Voith, B., et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78:4 (2005), 412–421.
52. 52 Kubitza, D., Becka, M., Wensing, G., et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:12 (2005), 873–880.
53. 53 Burghaus, R., Coboeken, K., Gaub, T., et al. Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. PLoS One, 6(4), 2011, e17626.
54. 54 Weinz, C., Schwarz, T., Kubitza, D., et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 37:5 (2009), 1056–1064.
55. 55 Adelmann, D., Wiegele, M., Wohlgemuth, R.K., et al. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. Thromb Res 134:4 (2014), 918–923.
56. 56 Arachchillage, D.R., Mackie, I.J., Efthymiou, M., et al. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost 13:7 (2015), 1264–1273.
57. 57 Asmis, L.M., Alberio, L., Angelillo-Scherrer, A., et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests—a study in 9 Swiss laboratories. Thromb Res 129:4 (2012), 492–498.
58. 58 Attard, C., Monagle, P., Kubitza, D., et al. The in vitro anticoagulant effect of rivaroxaban in children. Thromb Res 130:5 (2012), 804–807.
59. 59 Attard, C., Monagle, P., Kubitza, D., et al. The in-vitro anticoagulant effect of rivaroxaban in neonates. Blood Coagul Fibrinolysis 25:3 (2014), 237–240.
60. 60 Barrett, Y.C., Wang, Z., Frost, C., et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104:6 (2010), 1263–1271.
61. 61 Dale, B.J., Ginsberg, J.S., Johnston, M., et al. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. J Thromb Haemost 12:11 (2014), 1810–1815.
62. 62 Douxfils, J., Mullier, F., Loosen, C., et al. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 130:6 (2012), 956–966.
63. 63 Douxfils, J., Tamigniau, A., Chatelain, B., et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 110:4 (2013), 723–731.
64. 64 Du, S., Harenberg, J., Krämer, S., Krämer, R., Wehling, M., Weiss, C., Measurement of non-vitamin K antagonist oral anticoagulants in patient plasma using Heptest-STAT coagulation method. Ther Drug Monit 37:3 (2015), 375–380.
65. 65 Du, S., Kramer, S., Giese, C., et al. Chromogenic assays for measurement of rivaroxaban from EDTA anticoagulated plasma samples. Thromb Haemost 113:5 (2015), 1149–1151.
66. 66 Francart, S.J., Hawes, E.M., Deal, A.M., et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost 111:6 (2014), 1133–1140.
67. 67 Frost, C., Song, Y., Barrett, Y.C., et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol 6 (2014), 179–187.
68. 68 Gerotziafas, G.T., Baccouche, H., Sassi, M., et al. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res 129:1 (2012), 101–103.
69. 69 Gerotziafas, G.T., Elalamy, I., Depasse, F., et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 5:4 (2007), 886–888.
70. 70 Girgis, I.G., Patel, M.R., Peters, G.R., et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. J Clin Pharmacol 54:8 (2014), 917–927.
71. 71 Gosselin, R.C., Adcock Funk, D.M., Taylor, J.M., et al. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med 138:12 (2014), 1680–1684.
72. 72 Gosselin, R.C., Francart, S.J., Hawes, E.M., et al. Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level?. Ann Pharmacother 49:7 (2015), 777–783.
73. 73 Harder, S., Parisius, J., Picard-Willems, B., Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res 123:2 (2008), 396–403.
74. 74 Harenberg, J., Kramer, R., Giese, C., et al. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis 32:3 (2011), 267–271.
75. 75 Harenberg, J., Marx, S., Kramer, R., et al. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis 22:8 (2011), 637–641.
76. 76 Hillarp, A., Baghaei, F., Fagerberg Blixter, I., et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 9:1 (2011), 133–139.
77. 77 Jourdi, G., Siguret, V., Martin, A.C., et al. Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban. Thromb Haemost 114:1 (2015), 78–86.
78. 78 Kluft, C., Meijer, P., Kret, R., et al. Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban. Int J Lab Hematol 35:4 (2013), 379–384.
79. 79 Korber, M.K., Langer, E., Ziemer, S., et al. Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study. Clin Appl Thromb Hemost 20:7 (2014), 735–740.
80. 80 Molenaar, P.J., Dinkelaar, J., Leyte, A., Measuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 50:10 (2012), 1799–1807.
81. 81 Mueck, W., Becka, M., Kubitza, D., et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor—in healthy subjects. Int J Clin Pharmacol Ther 45:6 (2007), 335–344.
82. 82 Mueck, W., Borris, L.C., Dahl, O.E., et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100:3 (2008), 453–461.
83. 83 Mueck, W., Eriksson, B.I., Bauer, K.A., et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor—in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 47:3 (2008), 203–216.
84. 84 Mueck, W., Lensing, A.W., Agnelli, G., et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50:10 (2011), 675–686.
85. 85 Novak, M., Schlagenhauf, A., Bernhard, H., et al. Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma. Blood Coagul Fibrinolysis 22:7 (2011), 588–592.
86. 86 Rathbun, S., Tafur, A., Grant, R., et al. Comparison of methods to determine rivaroxaban anti-factor Xa activity. Thromb Res 135:2 (2015), 394–397.
87. 87 Samama, M.M., Contant, G., Spiro, T.E., et al. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 18:2 (2012), 150–158.
88. 88 Samama, M.M., Contant, G., Spiro, T.E., et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107:2 (2012), 379–387.
89. 89 Samama, M.M., Martinoli, J.L., LeFlem, L., et al. Assessment of laboratory assays to measure rivaroxaban: an oral, direct factor Xa inhibitor. Thromb Haemost 103:4 (2010), 815–825.
90. 90 Tripodi, A., Chantarangkul, V., Guinet, C., et al. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 9:1 (2011), 226–228.
91. 91 Wolzt, M., Gouya, G., Kapiotis, S., et al. Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. Thromb Res 132:2 (2013), 240–247.
92. 92 Xu, X.S., Moore, K., Burton, P., et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol 74:1 (2012), 86–97.
93. 93 Mani, H., Rohde, G., Stratmann, G., et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 108:1 (2012), 191–198.
94. 94 Frost, C., Nepal, S., Wang, J., et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 76:5 (2013), 776–786.
95. 95 Eliquis [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2012. http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed September 14, 2015.
96. 96 Barrett, Y.C., Wang, Z., Knabb, R.M., A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost 19:5 (2013), 522–528.
97. 97 Becker, R.C., Yang, H., Barrett, Y., et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban: an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 32:2 (2011), 183–187.
98. 98 Gouin-Thibault, I., Flaujac, C., Delavenne, X., et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays—a multicentre French GEHT study. Thromb Haemost 111:2 (2014), 240–248.
99. 99 Skeppholm, M., Al-Aieshy, F., Berndtsson, M., et al. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res 136:1 (2015), 148–153.
100. 100 Martin, A.C., Gouin-Thibault, I., Siguret, V., et al. Multimodal assessment of non-specific hemostatic agents for apixaban reversal. J Thromb Haemost 13:3 (2015), 426–436.
101. 101 Tripodi, A., Padovan, L., Veena, C., et al. How the direct oral anticoagulant apixaban affects thrombin generation parameters. Thromb Res 135:6 (2015), 1186–1190.
102. 102 Weitz, J.I., Connolly, S.J., Patel, I., et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 104:3 (2010), 633–641.
103. 103 Fukuda, T., Honda, Y., Kamisato, C., et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 107:2 (2012), 253–259.
104. 104 Furugohri, T., Isobe, K., Honda, Y., et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 6:9 (2008), 1542–1549.
105. 105 Furugohri, T., Sugiyama, N., Morishima, Y., et al. Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system. Thromb Haemost 106:6 (2011), 1076–1083.
106. 106 Honda, Y., Morishima, Y., Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: a potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists. Thromb Res 135:5 (2015), 958–962.
107. 107 Mendell, J., Noveck, R.J., Shi, M., A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol 75:4 (2013), 966–978.
108. 108 Mendell, J., Tachibana, M., Shi, M., et al. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 51:5 (2011), 687–694.
109. 109 Morishima, Y., Kamisato, C., Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol 143:2 (2015), 241–247.
110. 110 Noguchi, K., Morishima, Y., Takahashi, S., et al. Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban. Blood Coagul Fibrinolysis 26:2 (2015), 117–122.
111. 111 Ogata, K., Mendell-Harary, J., Tachibana, M., et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50:7 (2010), 743–753.
112. 112 Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 385:9984 (2015), 2288–2295.
113. 113 Samama, M.M., Mendell, J., Guinet, C., et al. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res 129:4 (2012), e77–e82.
114. 114 Wolzt, M., Samama, M.M., Kapiotis, S., et al. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. Thromb Haemost 105:6 (2011), 1080–1090.
115. 115 Zafar, M.U., Vorchheimer, D.A., Gaztanaga, J., et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 98:4 (2007), 883–888.
116. 116 Favaloro, E.J., Bonar, R., Butler, J., et al. Laboratory testing for the new oral anticoagulants: a review of current practice. Pathology 45:4 (2013), 435–437.
117. 117 Zantek, N.D., Hayward, C.P., Simcox, T.G., Smock, K.J., Hsu, P., Van Cott, E.M., An assessment of the state of current practice in coagulation laboratories. Am J Clin Pathol 146:3 (2016), 378–383.
118. 118 Pathologists CoA. Surveys Participant Summary for CGE, CGL, GCS, and ACM. College of American Pathologists, Northfield, IL. 2013.
119. 119 Pathologists CoA. Anticoagulant Monitoring Dabigatran, Fondaparinux and Rivaroxaban. ACM-A 2016 Participant Summary. 2016.
120. 120 Ezekowitz, M.D., Reilly, P.A., Nehmiz, G., et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 100:9 (2007), 1419–1426.
121. 121 van Ryn, J., Stangier, J., Haertter, S., et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor—interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:6 (2010), 1116–1127.